Eri T Kato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/710389/publications.pdf

Version: 2024-02-01

24 papers

8,934 citations

14 h-index

623734

713466 21 g-index

24 all docs

24 docs citations

times ranked

24

8812 citing authors

#	Article	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	27.0	4,159
2	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	13.7	1,958
3	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	27.0	780
4	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
5	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	11.4	482
6	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
7	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	215
8	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	2.7	117
9	<scp>DECLAREâ€TIMI</scp> 58: Participants' baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	4.4	96
10	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVEâ€IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association, 2017, 6, .	3.7	43
11	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Research Reviews, 2019, 49, 115-124.	10.9	34
12	Important Regulatory Role of Activated Platelet-Derived Procoagulant Activity in the Propagation of Thrombi Formed Under Arterial Blood Flow Conditions. Circulation Journal, 2009, 73, 540-548.	1.6	27
13	The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 468-474.	1.0	18
14	Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrast-induced nephropathy: report of two cases. Cardiovascular Intervention and Therapeutics, 2011, 26, 83-88.	2.3	16
15	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	6.3	15
16	Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials. International Journal of Heart Failure, 2020, 2, 12.	2.7	15
17	Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus― Circulation, 2019, 140, e740-e741.	1.6	6
18	Direct comparison of optical coherence tomography and high-definition 60-MHz intravascular ultrasound imaging of intra-procedural stent thrombosis in a patient with acute coronary syndrome. Cardiovascular Revascularization Medicine, 2019, 20, 365-367.	0.8	5

#	Article	IF	CITATION
19	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends in Cardiovascular Medicine, 2021, 31, 101-108.	4.9	5
20	A method and preliminary results of <i>in silico</i> computer simulation for the formation of mix thrombi with platelet and fibrin. Journal of Biorheology, 2017, 31, 30-34.	0.5	4
21	Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent Implantation. American Journal of Cardiology, 2022, 162, 13-23.	1.6	1
22	Potential difficulty for accurate categorization of drug-eluting stent thrombosis without coronary angiography: unignorable involvement of the cases with new onset acute myocardial infarction occurred in target vessels. Cardiovascular Intervention and Therapeutics, 2011, 26, 109-116.	2.3	0
23	A simple method preventing tangling of the guidewires during percutaneous coronary intervention for bifurcation lesions. Cardiovascular Intervention and Therapeutics, 2011, 26, 117-123.	2.3	0
24	Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization. JACC Asia, 2022, , .	1.5	0